References
- Cicero TJ, Kurtz SP, Surratt HL, Ibenaz GE, Ellis MS, Levi-Minzi MA, Inciardi JA. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues 2011;11:283–304
- Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Diseases 2102;31:207–225
- Wanderer JP, Bateman BT, Rathmell JP. Opioid use is rising. Anesthesiology 2014;121:(A23)
- Griffin OH, Spillane, JF. Pharmaceutical regulation failures and changes: lessons learned from OxyContin abuse and diversion. J Drug Issues 2012;43:164--175
- Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2011 National Survey on Drug Use and Health: summary of national findings (NSDUH Series H-44, HHS Publication No. SMA 12-4713). Rockville, MD: SAMHSA; 2012
- Chen LH, Hedegaard H, Warner M. QuickStats: number of deaths from poisoning, drug poisoning, and drug poisoning involving opioid analgesics – United States, 1999–2010. MMWR 2013:234
- Inciardi JA, Goode JL. OxyContin and prescription drug abuse: miracle medicine or problem drug. Consum Res 2003;7:17--21
- Muhuri PK, Gfroerer JC, Davies MC. Associations of nonmedical pain reliever use and initiation of heroin use in the US Center for Behavioral Health Statistics and quality data review. SAMHSA 2013. Available at: http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.htm
- Pollini RA, Banta-Green CJ, Cuevas-Mota J, Metzner M, Teshale E, Garfein RS. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabilitat 2011;2:173–180
- National Institute on Drug Abuse (NIDA). Epidemiologic trends in drug abuse. In: Proceedings of the Community Epidemiology Work Group, January 2012. Bethesda, MD: NIDA
- Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Ling W. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment with Agonist Replacement Therapies (START). J Stud Alcohol Drugs 2013;74:605–613
- Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Data System Rev 2009;3:CD002209
- Noysk B, Sun H, Evans E, Marsh DC, Anglin MD, Hser Y, Anis AH. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction 2012;107:1621--1629
- Wesson DR, Smith DE. Buprenorphine in the treatment of opioid dependence. J Psychoact Drugs 2010;42:161–176
- Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, et al. Neonatal abstinence syndrome after exposure to methadone or buprenorphine. New Eng J Med 2010;363:2320–2331
- Jackson TR. Treatment practice and research issues in improving opioid treatment outcomes. Sci Pract Perspect 2002;1:22–28
- Minozzi S, Amato L, Vecchi S, Davoli, M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Data Systemat Rev 2013;12:CD006318
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo versus methadone maintenance for opioid dependence. Cochrane Data Systemat Rev 2014;2:CD002207
- Lipsky S, Krupski A, Roy-Byrne P, Lucenko B, Mancuso D, Huber A. Effect of co-occurring disorders and intimate partner violence on substance abuse treatment outcomes. J Subst Abuse Treat 2010;38:231–244
- Fitzsimons H, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent women. J Subst Abuse Treat 2007;32:19–25